ALNYCongressional Stock Trades
Alnylam Pharmaceuticals, Inc.
Pharmaceutical Preparations
Congressional stock trades in Alnylam Pharmaceuticals, Inc. (ALNY) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
2
Politicians Trading
2
Last Traded
Aug 11, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Cory A. BookerD | Sep 9, 2026 | Aug 11, 2026 | Sell | $1,001 - $15,000 | -28.57% |
Price History
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
2 members of Congress have disclosed 2 trades in Alnylam Pharmaceuticals, Inc. (ALNY). Most active: Cory A. Booker (1), Jefferson Shreve (1).
Across all disclosures, members of Congress reported 0 purchases and 2 sales of Alnylam Pharmaceuticals, Inc. (ALNY). The most recent trade was on Aug 11, 2026.
Cory A. Booker disclosed selling Alnylam Pharmaceuticals, Inc. (ALNY) on Aug 11, 2026, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.